Share-based Payment Arrangement, Expense of Rubius Therapeutics, Inc. from 31 Dec 2016 to 31 Dec 2022
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
- Summary
-
Rubius Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2016 to 31 Dec 2022.
- Rubius Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2022 was $1,316,000, a 114% decline year-over-year.
- Rubius Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2022 was $15,783,000, a 56% decline year-over-year.
- Rubius Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $15,783,000, a 56% decline from 2021.
- Rubius Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $35,610,000, a 5.8% increase from 2020.
- Rubius Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $33,665,000, a 18% decline from 2019.
- Source SEC data
- View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)
Rubius Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2022 | $15,783,000 | $1,316,000 | -$10,498,000 | -114% | 01 Oct 2022 | 31 Dec 2022 | 10-K | 27 Feb 2023 | 2022 | FY |
| Q3 2022 | $26,281,000 | $3,798,000 | -$4,391,000 | -54% | 01 Jul 2022 | 30 Sep 2022 | 10-Q | 09 Nov 2022 | 2022 | Q3 |
| Q2 2022 | $30,672,000 | $5,041,000 | -$4,556,000 | -47% | 01 Apr 2022 | 30 Jun 2022 | 10-Q | 09 Aug 2022 | 2022 | Q2 |
| Q1 2022 | $35,228,000 | $8,260,000 | -$382,000 | -4.4% | 01 Jan 2022 | 31 Mar 2022 | 10-Q | 10 May 2022 | 2022 | Q1 |
| Q4 2021 | $35,610,000 | $9,182,000 | +$242,000 | +2.7% | 01 Oct 2021 | 31 Dec 2021 | 10-K | 27 Feb 2023 | 2022 | FY |
| Q3 2021 | $35,368,000 | $8,189,000 | +$204,000 | +2.6% | 01 Jul 2021 | 30 Sep 2021 | 10-Q | 09 Nov 2022 | 2022 | Q3 |
| Q2 2021 | $35,164,000 | $9,597,000 | +$1,345,000 | +16% | 01 Apr 2021 | 30 Jun 2021 | 10-Q | 09 Aug 2022 | 2022 | Q2 |
| Q1 2021 | $33,819,000 | $8,642,000 | +$154,000 | +1.8% | 01 Jan 2021 | 31 Mar 2021 | 10-Q | 10 May 2022 | 2022 | Q1 |
| Q4 2020 | $33,665,000 | $8,940,000 | -$1,891,000 | -17% | 01 Oct 2020 | 31 Dec 2020 | 10-K | 27 Feb 2023 | 2022 | FY |
| Q3 2020 | $35,556,000 | $7,985,000 | -$2,373,000 | -23% | 01 Jul 2020 | 30 Sep 2020 | 10-Q | 08 Nov 2021 | 2021 | Q3 |
| Q2 2020 | $37,929,000 | $8,252,000 | -$2,352,000 | -22% | 01 Apr 2020 | 30 Jun 2020 | 10-Q | 09 Aug 2021 | 2021 | Q2 |
| Q1 2020 | $40,281,000 | $8,488,000 | -$990,000 | -10% | 01 Jan 2020 | 31 Mar 2020 | 10-Q/A | 20 Aug 2021 | 2021 | Q1 |
| Q4 2019 | $41,271,000 | $10,831,000 | +$1,705,000 | +19% | 01 Oct 2019 | 31 Dec 2019 | 10-K | 25 Feb 2022 | 2021 | FY |
| Q3 2019 | $39,566,000 | $10,358,000 | +$471,000 | +4.8% | 01 Jul 2019 | 30 Sep 2019 | 10-Q | 09 Nov 2020 | 2020 | Q3 |
| Q2 2019 | $39,095,000 | $10,604,000 | +$4,702,000 | +80% | 01 Apr 2019 | 30 Jun 2019 | 10-Q | 10 Aug 2020 | 2020 | Q2 |
| Q1 2019 | $34,393,000 | $9,478,000 | +$6,865,000 | +263% | 01 Jan 2019 | 31 Mar 2019 | 10-Q | 11 May 2020 | 2020 | Q1 |
| Q4 2018 | $27,528,000 | $9,126,000 | 01 Oct 2018 | 31 Dec 2018 | 10-K | 23 Feb 2021 | 2020 | FY | ||
| Q3 2018 | $9,887,000 | +$5,750,000 | +139% | 01 Jul 2018 | 30 Sep 2018 | 10-Q | 14 Nov 2019 | 2019 | Q3 | |
| Q2 2018 | $5,902,000 | 01 Apr 2018 | 30 Jun 2018 | 10-Q | 13 Aug 2019 | 2019 | Q2 | |||
| Q1 2018 | $2,613,000 | 01 Jan 2018 | 31 Mar 2018 | 10-Q | 15 May 2019 | 2019 | Q1 | |||
| Q3 2017 | $4,137,000 | 01 Jul 2017 | 30 Sep 2017 | 10-Q | 13 Nov 2018 | 2018 | Q3 |
Rubius Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2022 | $15,783,000 | -$19,827,000 | -56% | 01 Jan 2022 | 31 Dec 2022 | 10-K | 27 Feb 2023 | 2022 | FY |
| 2021 | $35,610,000 | +$1,945,000 | +5.8% | 01 Jan 2021 | 31 Dec 2021 | 10-K | 27 Feb 2023 | 2022 | FY |
| 2020 | $33,665,000 | -$7,606,000 | -18% | 01 Jan 2020 | 31 Dec 2020 | 10-K | 27 Feb 2023 | 2022 | FY |
| 2019 | $41,271,000 | +$13,743,000 | +50% | 01 Jan 2019 | 31 Dec 2019 | 10-K | 25 Feb 2022 | 2021 | FY |
| 2018 | $27,528,000 | +$9,625,000 | +54% | 01 Jan 2018 | 31 Dec 2018 | 10-K | 23 Feb 2021 | 2020 | FY |
| 2017 | $17,903,000 | +$17,756,000 | +12079% | 01 Jan 2017 | 31 Dec 2017 | 10-K | 12 Mar 2020 | 2019 | FY |
| 2016 | $147,000 | 01 Jan 2016 | 31 Dec 2016 | 10-K | 28 Mar 2019 | 2018 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.